AzTrials
AzTrials

Liver CirrhosisNCT01494220

Validation of the Bispectral Index Monitor During Living Donor Liver Transplantation

An observational study of Liver Cirrhosis, run by Mansoura University at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Bispectral index (BIS) monitoring during living donor liver transplantation (LDLT) may be influenced with several factors rather than the depth of anesthesia such as bradycardia, hypotension, hypothermia, and mixed venous oxygen saturation (SvO2). Read more about this study

Who is it for?
Ages 20 to 50 years
Conditions the study is for
Liver Cirrhosis
What is being tested?
Bispectral index monitoring (BIS)
Type of treatment
Medical device
How many people
42 participants
Where
1 siteEgypt
Study dates
Jun 2007to Feb 2011
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 50 years
  • All sexes
  • No healthy volunteers
  • Adult

Study population: Mansoura University Liver Transplantation Program

Who may be able to join

  • American Society of Anesthesiologists physical class III-IV
  • aged 20-50 years
  • severe liver dysfunction
  • Child-Pugh Class C
  • liver cirrhosis

Who cannot join

  • preexisting significant neuropsychiatric
  • cardiac diseases
  • pulmonary diseases
  • renal diseases
  • neuromuscular diseases
  • electrolyte disorders
Show all 18Show fewer
  • body mass index greater than 35 kg/m2
  • pregnancy
  • use of antipsychotics
  • use of antidepressants
  • alcohol abuse
  • drug abuse
  • previous transplantation
  • those with hepatic encephalopathy
  • recent cognitive dysfunction during the past three months
  • fulminant hepatic failure
  • hepato-pulmonary syndrome
  • pulmonary hypertension

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • College of Medicine, Mansoura University

    Al Mansurah, DK, 050

Other trials in Egypt

About this study

Bispectral index (BIS) monitoring during living donor liver transplantation (LDLT) may be influenced with several factors rather than the depth of anesthesia such as bradycardia, hypotension, hypothermia, and mixed venous oxygen saturation (SvO2). The investigators tested the validity and the independent factors which may alter of BIS readings during LDLT.

Up to the investigators best knowledge, the independent predictors for BIS monitoring were not identified yet during the three phases of liver transplantation.

Read the detailed description

Forty two American Society of Anesthesiologists physical class III-IV patients aged 20-50 years with severe liver dysfunction (Child-Pugh Class C) due to liver cirrhosis undergoing living donor liver transplantation in the Mansoura University Liver Transplantation Program from 2007 to 2010 were included in this prospective, observational study after obtaining approval of the local ethical committee and an informed written consent from all participants. The etiology of liver cirrhosis was hepatitis C, Budd Chiari syndrome, hepatocellular carcinoma and autoimmune in all patients.

Anesthetic technique was standardized for all patients. All patients received preoperative intravenous 40 mg of pantoprazole. Patients were monitored with three leads electrocardiography, pulse oximeter, and noninvasive blood pressure. BIS recording electrodes (Aspect Medical Systems. Inc., One Upland Road, Norwood, MA 02062 USA) were applied to the forehead of each patient according to the manufacturer recommendations. The BIS monitor was masked with opaque sheet and BIS data was recorded prior to induction of general anesthesia then continued throughout the procedure. All information obtained from the BIS monitor was continuously downloaded to a computer for offline analysis. The patient's management was not guided by the changes in BIS readings. Before induction of anesthesia, all patients were premedicated with 1-2 mg of intravenous midazolam.

Independent anesthetists, who were not involved in the collection and analysis of the patient's data, provided the perioperative anesthetic management. After preoxygenation, anesthesia was induced with lidocaine 0.75 mg/kg, propofol 1.5-2.0 mg/kg and fentanyl 2µg/kg. Rocuronium 1-1.2 mg/kg was given to suppress the first response on the train-of-four (TOF) stimulations of the ulnar nerve. After tracheal intubation, the lungs were ventilated with an inspired fraction of oxygen (FiO2) of 0.4 to maintain an arterial carbon dioxide tension at 35-45 mm Hg and monitoring of end-tidal carbon dioxide and sevoflurane concentration, direct arterial pressure monitoring through a radial artery catheter and a tympanic membrane temperature were implemented.

A 7.5 Fr continuous thermodilution fiberoptic pulmonary artery catheter (CCO/SvO2) Edwards Life Science, Irvine, CA, USA) was floated through the right internal jugular vein to the right pulmonary artery using waveform and fluoroscopic guidance to measure cardiac output using Angstrom AS5 Monitor (Datex - Ohmeda AS5, Microvitec Display LTD, Bolling Road, Bradford, UK). The final position was confirmed by fluoroscopy and when PAOP less than pulmonary artery diastolic pressure (PADP).

Anesthesia was maintained with 0.5-1.5 minimum alveolar concentration (MAC) of sevoflurane and continuous intravenous infusion of fentanyl (1-3 µg/kg/h) titrated to maintain the mean arterial blood pressure (MAP) and heart rate (HR) within 20% of their baseline values. Rocuronium 0.1-0.3 mg/kg/h was used to maintain suppression of the second twitch in the TOF.

Normothermia was maintained using intravenous infusions of warm fluid and blood products and water-filled thermal mattress according to the authors' protocol. Fluid boluses were given in 250 ml aliquots of either 5% hydroxyethyl Starch 130/0.4 (Voluven® 6%, Fresenius Kabi, Bad Hombourg, Germany) as needed to maintain the CVP and/or PAOP between 5 and 7 mm Hg and the stroke volume (SV) within 20% of its baseline value. Albumin 5% was given as needed to treat hypoalbuminemia. Transfusion of salvaged blood from the cell saver and packed red blood cells was administered as clinically indicated to maintain a hemoglobin level ≥7 g/dL. Intraoperative changes in electrolyte levels and acid-base balance were regularly monitored and treated as appropriate. Hemodynamic control was standardized according to the authors' center protocol. Hypotension (MAP decreased < 20% from the mean baseline and SVR < 600 dyne.sec-1.cm-5) was treated with boluses of fluids, ephedrine 5 mg, or epinephrine 5 µg, as needed. Norepinephrine infusion was used for persistent hypotension with low SVR. Dobutamine or epinephrine infusion was administered if the MAP was ≥ 70 mm Hg, CVP and/or PAOP ≥ 7 mm Hg and the cardiac output was < 4.0 L. min-1. Hypertension (MAP increased > 20% from the mean baseline) was treated with deepening of anesthesia, bolus doses of nitroglycerin 0.05 mg or labetalol 20 mg. Tachycardia (HR > 20% from the baseline values) was treated with boluses of esmolol 20 mg.

All operations were performed by the same surgeons using the piggyback technique. After portal vein clamping, infusion rates of fentanyl and rocuronium were reduced by approximately 50%. Fentanyl and rocuronium infusions were discontinued after peritoneal closure. After completion of skin closure, sevoflurane was discontinued. The patients were transferred to the ICU immediately after surgery, while intubated and postoperative analgesia was achieved with rescue boluses of fentanyl 0.5 µg/kg when needed.

Extubation criteria included cooperative, alertness, train-of-four ratio ≥ 0.9, spontaneous breathing with tidal volume > 5 mL/kg, respiratory rate > 10 and < 28 breaths/min, maximum inspiratory pressure ≤ -20 cm H2O, stable hemodynamics, minimal bleeding, core temperature > 35.5°C, urine output > 0.5 mL/Kg/h, arterial carbon dioxide tension ≤ 45 mm Hg, arterial oxygen tension > 100 mm Hg and FiO2 < 50%.

On the second postoperative day, the patients were asked about perioperative awareness and recall by asking three simple questions using standard interview "What was the last thing you remembered happening before you went to sleep? What is the first thing you remember happening on waking? Did you dream or have any other experiences whilst you were asleep?" Another investigator, who was not involved in the patient's management, collected the saved patients' data. Preoperative MELD score, durations of warm ischemia and anhepatic phase, intraoperative blood loss and fentanyl consumption were collected. Preoperatively (baseline) absolute values and intraoperative average values for BIS, Et-Sevo, heart rate (HR), MAP, CVP, MPAP, CO, PAOP, SVR, PVR, core temperature, pH, PaCO2, PaO2, SaO2 SvO2, and PvO2 were recorded during hepatic dissection, anhepatic, and neohepatic phases and during surgical closure. Postoperative total bilirubin, albumin level, liver enzymes (AST, ALT, GGT, and alkaline phosphatase), PT, factors V and VII, time to extubation, ICU and hospital length of stays, neurological complication, encephalopathy and 3 months-mortality were recorded.

Data were tested for normality using the Kolmogorov-Smirnov test. Repeated-measures analysis of variance was used for analysis of serial changes in the patients' data at different times. Fisher exact test was used for categorical data. Postulated independent predictors of BIS readings included age, gender, MELD score, durations of surgical phases and warm ischemia, Et-Sevo, average of intraoperative hemodynamic, temperature, oxygenation and acid base variables, intraoperative blood loss and fentanyl consumption, were examined in a stepwise manner into a multiple regression model, with entry and retention set at a significance level of P < 0.05 and removal set at P ≥ 0.1. Moreover, multivariate logistic regression was done to identify the correlations between BIS values and blood loss, time to tracheal extubation, postoperative liver function and coagulation variables, ICU length of stay, and 3 months-mortality.

To evaluate the accuracy of BIS in predicting survival rate after liver transplantation, receiver operating characteristic (ROC) curves were generated to describe the performance characteristics of the BIS readings during different phases of surgery in predicting the survival outcome. An ROC area of 1.0 is characteristic of an ideal model, whereas an area of 0.5 indicates a model of no diagnostic value. Cutoff values for mortality with the best diagnostic sensitivity and specificity were derived from the ROC curve analyses. Unweighted accuracy ((sensitivity + specificity) / 2) was also reported.

The studied patients were further divided according to their outcome variables into survivors (n = 32) and non-survivors (n = 10) subgroups. Independent Student-t- and Mann Whitney tests were used as appropriate. Data were expressed as mean (standard deviation), number (%), or median [range]. A value of P < 0.05 was considered to represent statistical significance.

Conditions
Liver Cirrhosis
Being tested
Bispectral index monitoring (BIS)
Keywords
Bispectral index; anesthesia, liver transplantation, independent factors, outcome, Living donor liver transplantation
Medical subject headings
Liver Cirrhosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Bispectral index monitoring (BIS)Device

    BIS recording electrodes (Aspect Medical Systems. Inc., One Upland Road, Norwood, MA 02062 USA) were applied to the forehead of each patient according to the manufacturer recommendations. The BIS monitor was masked with opaque sheet and BIS data was recorded prior to induction of general anesthesia then continued throughout the procedure. All information obtained from the BIS monitor was continuously downloaded to a computer for offline analysis. The patient's management was not guided by the changes in BIS readings.

Study groups in NCT01494220
Study groupRoleWhat they receive
Living donor liver transplantationPatients undergoing living donor liver transplantation in the Mansoura University Liver Transplantation Program from 2007 to 2010
Receives: Device: Bispectral index monitoring (BIS)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Intraoperative blood loss

    Intraoperative blood loss

    Measured: up to 1 hr after surgery

  2. Changes from Baseline in hemodynamic variables

    Hemodynamic changes

    Measured: 30 min during hepatectomy, 30 min during anhepatic, 30 min during neohepatic phases

  3. Changes from Baseline in Temperature variables

    Temperature

    Measured: 30 min during hepatectomy, 30 min during anhepatic, 30 min during neohepatic phases

  4. Changes in blood gases variables from baseline

    Blood gases

    Measured: 30 min during hepatectomy, 30 min during anhepatic, 30 min during neohepatic phases

Secondary outcomes (3)
  1. postoperative liver function tests

    correlation between BIS values and postoperative liver function tests

    Measured: up to 6 hrs after surgery

  2. postoperative coagulation factors

    correlation between BIS and postoperative coagulation factors

    Measured: up to 6 hrs after surgery

  3. 3-months mortality

    correlation between BIS values and 3-months mortality

    Measured: up to 3 months after surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Dec 2011 (estimated)
  2. Study startJun 2007
  3. Primary completionMar 2010
  4. Study completionFeb 2011

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
42 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01494220
Sponsor's protocol ID
2007-5
Other IDs
Liver Transplantation Unit 3
Status last verified
Apr 2012
First submitted
13 Dec 2011
Last updated
4 Apr 2012
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

An observational study of Liver Cirrhosis, run by Mansoura University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 4 Apr 2012. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Intraoperative blood loss (time frame: up to 1 hr after surgery). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Apr 2012.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in